Kalohexis 710GO data highlight a differentiated obesity mechanism as Phase 1 moves ahead
Read how Kalohexis’ 710GO could challenge GLP-1 obesity drugs with dual MC3R/MC4R activation, lean-mass sparing and durability.
Pharma & Biotech
Pharma & Biotech
Is Biocodex’s Fullify the first probiotic to challenge GLP-1 drugs in the consumer weight-loss space?
Biocodex launches Fullify, a gut-brain axis probiotic for appetite control. Find out what this means for weight loss, microbiome science, and the supplement industry.
Pharma & Biotech
Will TETRAPHARM’s TPC-026 unlock the chronic-care gap in metabolic disorders?
Can TPC-026 fill the gap after GLP-1s? Find out how TETRAPHARM’s novel compound could reshape long-term metabolic care.
Pharma & Biotech
Can Genentech’s CT-388 challenge obesity drug giants with 22.5% weight loss and β-arrestin bias?
Genentech’s CT-388 hit 22.5% weight loss in Phase II. Find out what this means for obesity drugs, clinical durability, and market strategy in 2026.
Pharma & Biotech
Mazdutide shows weight loss efficacy in Chinese teens: Phase 1b results raise hopes for approval
Innovent Biologics has reported that mazdutide, its dual GLP-1 and glucagon receptor agonist, achieved statistically significant reductions in both body mass index and weight in Chinese adolescents with obesity during a 12-week Phase 1b clinical trial. The trial met its primary endpoint, demonstrated a favorable safety profile, and paves the way for a Phase 3